Novo Nordisk raises 2017 forecasts despite continued US price pressure
Copenhagen
NOVO Nordisk, the world's leading maker of diabetes drugs, reported a better than expected profit on Wednesday driven by new diabetes and obesity drugs, though it said sale prices would remain under pressure in the United States.
The Danish drugmaker shocked markets in 2016 by cutting its long-term operating profit forecasts twice on the back of price pressures in its main US market, sending its shares down more than 40 per cent last year.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
TikTok tells advertisers: ‘We are not backing down’
EV automakers get reprieve in US tax credit rules
Nomura, Mizuho face losses on All Blue fund’s failed trades
Stablecoin Tether steps up monitoring in bid to combat illicit finance
HSBC asked by US$890 billion investor group to set energy goal
BHP’s biggest rivals sit on the sidelines of Anglo M&A drama